Adiponectin as a biomarker of systemic inflammatory response in smoker patients with stable and exacerbation phases of chronic obstructive pulmonary disease

Kırdar, Sevin; Serter, Mukadder; Ceylan, Emel; Şener, Aslı Gamze; Kavak, Tülay; Karadağ, Fisun

doi:10.1080/00365510802474400

Cited by 64 publications

(53 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…37 In patients with COPD, the anti-inflammatory effect of adiponectin is more marked in severe and very severe stages as well as during exacerbations. 38,39 In our study, the serum adiponectin concentration was significantly higher in patients with frequent exacerbations, which seems to confirm its role in systemic inflammation. Thus, evaluation of serum adiponectin may be helpful in the identification of patients at higher risk of exacerbation.…”

supporting

confidence: 77%

Effect of exacerbation frequency on body composition and serum ghrelin and adiponectin concentrations in patients with chronic obstructive pulmonary disease

Rubinsztajn¹,

Przybyłowski²,

Maskey-Warzęchowska³

et al. 2014

Polish Archives of Internal Medicine

View full text Add to dashboard Cite

supporting

confidence: 77%

Effect of exacerbation frequency on body composition and serum ghrelin and adiponectin concentrations in patients with chronic obstructive pulmonary disease

Rubinsztajn¹,

Przybyłowski²,

Maskey-Warzęchowska³

et al. 2014

Polish Archives of Internal Medicine

View full text Add to dashboard Cite

“…Eker et al [19] found that in stable COPD patients leptin levels were low and the frequency of insulin resistance was high compared with the controls, although no difference in body FM was determined between the study populations. In other studies where COPD patients and controls were well matched for age, gender and BMI, the circulating leptin levels were not significantly different between stable COPD patients and healthy controls [17,24,25,30,31,32]. However, Gaki et al [33] demonstrated that leptin levels were higher in COPD patients who used inhaled corticosteroids.…”

Section: Resultsmentioning

confidence: 95%

Circulating Leptin Concentrations in Patients with Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis

Zhou

Yuan

Zhang³

et al. 2013

Respiration

View full text Add to dashboard Cite

Background: Weight loss is a clinically important risk factor indicating a poor prognosis in chronic obstructive pulmonary disease (COPD). Leptin is an important regulator of food intake and energy expenditure. Objectives: To conduct a meta-analysis to determine whether the level of leptin is related to the disease status of COPD. Methods: Studies published before December 2012 were identified by searching PubMed, Embase and the Cochrane Database. Observational studies comparing circulating leptin levels between COPD patients and healthy controls were included. Data were independently extracted by two investigators and analyzed using Stata 12.0 software. Results: Ten articles were included in the meta-analysis. Circulating leptin levels were correlated with the body mass index (BMI) as well as percent fat mass in stable COPD patients. The correlation coefficient tended to be weaker during exacerbation. A positive correlation between leptin and tumor necrosis factor (TNF)-α levels was found in COPD exacerbations, while it disappeared in patients with stable disease. Most studies indicated that circulating leptin levels in stable COPD patients were not significantly different from those in healthy controls when adjusted for gender and BMI, whilst leptin levels tended to elevate in exacerbation groups. Conclusions: The normal regulatory mechanism of leptin is maintained in stable COPD patients despite weight loss. The additional correlation between leptin and TNF-α during exacerbations may support the closer association of leptin with changes in nutritional parameters and suggests its valuable role in the evaluation of systemic inflammatory responses in COPD patients during exacerbation, which merits further study.

show abstract

“…In humans, down regulation of adiponectin and its receptors is associated with systemic inflammation and extrapulmonary effects, such as weight loss, osteoporosis, adipose atrophy, and skeletal muscle atrophy associated with age [6] . Recent human studies have demonstrated a significant increase in serum adiponectin levels in COPD and a direct correlation of these levels to the severity of the disease [7,8] . Plasma adiponectin is increased in underweight patients with COPD and is inversely associated with body mass index, degree of airflow limitation, and adverse cardiovascular outcomes.…”

Section: Introductionmentioning

confidence: 99%

Genetic variants of CDH13 determine the susceptibility to chronic obstructive pulmonary disease in a Chinese population

Yuan

Zhang

et al. 2016

Acta Pharmacol Sin

View full text Add to dashboard Cite

Aim: Adiponectin has been implicated in the development of chronic obstructive pulmonary disease (COPD). The CDH13 gene encodes T-cadherin that is an adiponectin receptor, and genetic variants of CDH13 determine blood adiponectin levels. The aim of this study was to investigate the effects of CDH13 variants on COPD susceptibility in a Chinese population. Methods: Ten single-nucleotide polymorphisms (SNP) in CDH13 were screened using the SNaPshot method in 279 COPD patients and 367 control subjects. Association of genotypes or haplotypes constructed from these loci with COPD was analyzed in different genetic models. Results: Among the 10 SNPs tested, rs4783244 and rs12922394 exhibited significant differences in allele or genotype frequencies between COPD patients and control subjects, whereas 8 other SNPs did not. The minor allele T was associated with decreased risk of COPD in the recessive model at rs4783244 (OR=0.42, P=0.023) and in the dominant model at rs12922394 (OR=0.70, P=0.022). The genotype TT at either rs4783244 or rs12922394 was associated with a significantly low level of plasma adiponectin when compared to genotypes GG and CC (P<0.05). Haplotypes GC in block 1 (rs4783244-rs12922394) as well as GTAC and ATGT in block 3 (rs4783266-rs11640522-rs11646849-rs11860282) significantly increased the risk of COPD, whereas haplotypes TT in block 1, TG in block 2 (rs11646011-rs11640875) and ATGC in block 3 were protective against COPD. Conclusion: CDH13 genetic variants determine Chinese individuals' susceptibility to COPD and thus are efficient genetic biomarkers for early detection of COPD.

show abstract

Adiponectin as a biomarker of systemic inflammatory response in smoker patients with stable and exacerbation phases of chronic obstructive pulmonary disease

Abstract: Adiponectin may be a marker of low-grade systemic inflammatory response in COPD. A further rise in serum adiponectin in the exacerbation period denotes that this may also be a biomarker of the exacerbation phase as well as CRP and ESR.

Cited by 64 publications

References 32 publications

Effect of exacerbation frequency on body composition and serum ghrelin and adiponectin concentrations in patients with chronic obstructive pulmonary disease

Effect of exacerbation frequency on body composition and serum ghrelin and adiponectin concentrations in patients with chronic obstructive pulmonary disease

Circulating Leptin Concentrations in Patients with Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis

Genetic variants of CDH13 determine the susceptibility to chronic obstructive pulmonary disease in a Chinese population

Contact Info

Product

Resources

About